Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + docetaxel
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Afatinib + docetaxel is a **combination regimen** using the small-molecule tyrosine kinase inhibitor afatinib, which irreversibly inhibits the ErbB family of receptors (including EGFR/HER1, HER2, and HER4), with docetaxel, a taxane chemotherapy that stabilizes microtubules to inhibit cell division. This combination has been investigated primarily in patients with solid tumors, including advanced cancer, in phase I trials to determine dosing and safety. Pulsatile dosing schedules for afatinib have been explored to reduce toxicity. The combination is supported by preclinical evidence for enhanced antitumor activity. Afatinib is developed by Boehringer Ingelheim, and docetaxel was originally developed by Rhône-Poulenc Rorer (now part of Sanofi)[1][2][3].
- Other names
- afatinib and docetaxel
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)RNR (Ribonucleotide reductase)Microtubule
Beyond the preview
Go deeper on afatinib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + docetaxel.